Episealer® Talus registered for sale in Italy and Spain

Episurf Medical (NASDAQ: EPIS B) today announces that the company’s ankle implant Episealer® Talus, recently CE approved, is now additionally approved for sale in Italy and Spain. Notifications to applicable authorities have been completed through National Health Information System (NSIS) Database in Italy and CCPS (Comunicaciones de Productos Sanitaros) in Spain, which fulfils the regulatory requirements for distribution in the corresponding countries. Episealer® Talus is further undergoing registration in the Medical Device Registration portal Infarmed in Portugal and that registration is expected to be finalised shortly.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: